1:21 PM
 | 
Oct 17, 2017
 |  BC Extra  |  Company News

Syndax in menin-MLL deal with Allergan

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) obtained an exclusive, worldwide license to inhibitors of the menin-MLL fusion oncogene from the Vitae Pharmaceuticals Inc. subsidiary of Allergan plc (NYSE:AGN). Syndax plans to begin clinical trials in 2019 of the small molecules to treat acute leukemia patients with chromosomal rearrangements...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >